menu search

PDSB / PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary VersamuneĀ® and Infectimuneā„¢ T-cell activating technologies, today announced that it has changed the date of its previously announced 2021 fourth quarter and full year earnings release call from Wednesday, March 23, 2022 to 8:00 AM EDT on Thursday, March 31, 2022 as PDS Biotech needs additional time to complete its audit and file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Following the release, management will host a conference call to review the financial results and provide a business update. Read More
Posted: Mar 22 2022, 19:30
Author Name: GlobeNewsWire
Views: 103196

PDSB News  

PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why

By Zacks Investment Research
August 29, 2023

PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why

Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline can more_horizontal

PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study

By Seeking Alpha
August 14, 2023

PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study

PDS Biotechnology has achieved positive results in its phase 2 study of PDS0101 in combination with Merck's Keytruda for HPV16-positive head and neck more_horizontal

The Prognosis For PDS Biotechnology

By Seeking Alpha
August 13, 2023

The Prognosis For PDS Biotechnology

PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeli more_horizontal

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET

By GlobeNewsWire
June 5, 2023

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET

FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing more_horizontal

PDS Biotechnology: Promising Interim HNSCC Data Reaffirms Investment Prospects

By Seeking Alpha
May 27, 2023

PDS Biotechnology: Promising Interim HNSCC Data Reaffirms Investment Prospects

PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival ra more_horizontal

PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study

By Zacks Investment Research
May 26, 2023

PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study

PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients. more_horizontal

PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study

By Zacks Investment Research
May 19, 2023

PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study

PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer pati more_horizontal

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

By GlobeNewsWire
May 4, 2023

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a more_horizontal


Search within

Pages Search Results: